|Bid||22.61 x 900|
|Ask||22.79 x 1000|
|Day's Range||21.52 - 22.95|
|52 Week Range||20.30 - 53.70|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.20|
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
“The third quarter has been productive for AVROBIO,” commented Geoff MacKay, President and Chief Executive Officer of AVROBIO. “In a recent clinical data update on AVR-RD-01, we were pleased with the α‑galactosidase A (AGA) enzyme activity demonstrated in patients with Fabry disease. In addition, we have achieved our first regulatory milestone for our gene therapy for Gaucher disease as it advances towards the clinic.
CAMBRIDGE, Mass., Oct. 04, 2018 -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare.
AVROBIO, Inc. (AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company developing gene therapies to potentially cure rare diseases with a single dose, today announced that it has received no objection to its clinical trial application (CTA) from Health Canada for a Phase 1/2 clinical trial of AVR-RD-02, the Company’s gene therapy for Gaucher disease. AVR‑RD-02 is an ex vivo lentiviral gene therapy.
First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively; Patient ...
Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.